<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03316872</url>
  </required_header>
  <id_info>
    <org_study_id>PEMRAD</org_study_id>
    <nct_id>NCT03316872</nct_id>
  </id_info>
  <brief_title>Study of Pembrolizumab and Radiotherapy in Liver Cancer</brief_title>
  <official_title>Pembrolizumab and Stereotactic Radiotherapy Combined in Subjects With Advanced Hepatocellular Carcinoma - A Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 study whose purpose is to assess the efficacy of the combination of
      pembrolizumab and stereotactic body radiotherapy (SBRT) in patients with advanced
      hepatocellular carcinoma (HCC) who have experienced disease progression after treatment with
      sorafenib.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2018</start_date>
  <completion_date type="Anticipated">April 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate in non-irradiated tumor lesions</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab and Stereotactic Body Radiotherapy (SBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab, intravenously, at a dose of 200 mg, once every 3 weeks
SBRT starting Day 2 of Cycle 1 of pembrolizumab treatment, given in 5 fractions over 10-15 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab is a humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.</description>
    <arm_group_label>Pembrolizumab and Stereotactic Body Radiotherapy (SBRT)</arm_group_label>
    <other_name>KEYTRUDA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiotherapy (SBRT)</intervention_name>
    <description>SBRT involves delivery of high doses of radiation therapy in smaller fractions</description>
    <arm_group_label>Pembrolizumab and Stereotactic Body Radiotherapy (SBRT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide written informed consent/assent for the trial

          -  Be ≥18 years of age on day of signing informed consent.

          -  Have a histologically- or cytologically-confirmed diagnosis of hepatocellular
             carcinoma (HCC), and at least one measurable lesion.

          -  Have current liver function meeting Child Pugh Class A (5-6 points), with no
             encephalopathy or ascites.

          -  Have intrahepatic HCC amenable to stereotactic body radiotherapy (SBRT):

          -  maximum 10 lesions to be treated, and

          -  total tumor diameter to be treated &lt;20 cm

          -  No single liver tumor &gt;15 cm in diameter

          -  No evidence of common or main branch bile duct invasion

          -  No evidence of direct tumor extension into stomach, duodenum, small bowel, large bowel
             or diaphragm

          -  Smaller satellites of HCC or non-definite HCC need not be encompassed within SBRT
             volumes if needed to respect normal tissue limits.

          -  Be willing to provide tissue from a newly obtained core or excisional biopsy of a
             tumor lesion.

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Have demonstrated disease progression, after previous treatment with sorafenib for
             advanced or metastatic disease, lasting a minimum of 8 week period, allowing for
             appropriate interruptions and dose reductions.

          -  Have recovered (to ≤ grade 1) from prior toxicities related to previous treatments at
             the time of study enrollment, with the exception of alopecia or skin depigmentation.

          -  Be tested during screening for Hepatitis B-Virus surface antigen (HbsAg) status.
             Patients may be included in the study if they have adequately controlled hepatitis B

          -  Patients must be tested during study screening for hepatitis C virus (HCV) RNA status.
             Patients with chronic infection by HCV who are untreated are allowed on study. In
             addition, patients with successful HCV treatment are allowed as long as 4 weeks have
             passed between completion of HCV therapy and start of study treatment.

          -  Demonstrate adequate organ function.

          -  Women of child-producing potential must agree to use effective contraceptive methods
             prior to study entry, during study participation, and for at least 30 days after the
             last administration of study medication. A serum pregnancy test within 72 hours prior
             to the initiation of therapy will be required for women of childbearing potential. Men
             treated or enrolled on this trial must agree to use adequate contraception prior to
             and for 4 months after completion of pembrolizumab administration.

        Exclusion Criteria:

          -  Willing and able to provide written informed consent/assent for the trial

          -  Has received any second-line systemic therapy for advanced HCC after disease
             progression following sorafenib therapy, or has had prior radiotherapy to the proposed
             treatment field.

          -  Is currently participating and receiving experimental treatment as part of a clinical
             trial, or has participated in a study of an immune checkpoint inhibitor and received
             study therapy, or used an investigational device within 4 weeks of the first dose of
             treatment.

          -  Has had a previous solid organ transplant, a diagnosis of immunodeficiency, or is
             receiving systemic steroid therapy or any other form of immunosuppressive therapy
             within 7 days prior to the first dose of trial treatment.

          -  Has liver tumor not amenable to SBRT, or has had prior upper abdominal radiation
             therapy within planned volumes (exceeding standard tolerances).

          -  Has a histological or cytological diagnosis of fibrolamellar HCC, sarcomatoid HCC, or
             mixed cholangiocarcinoma-HCC.

          -  Has had prior radioembolization or other selective internal radiotherapy treatment to
             the liver.

          -  Has dual active HBV infection (HBsAg (+) and/or detectable HBV DNA) and HCV infection
             (anti-HCV Ab(+) and detectable HCV RNA) at study entry.

          -  Has had esophageal or gastric variceal bleeding within 3 months prior to study
             enrollment.

          -  Has had encephalopathy in the past 6 months, or has clinically apparent ascites at the
             time of study enrollment.

          -  Has a known history of active TB (Bacillus Tuberculosis).

          -  Hypersensitivity to pembrolizumab or any of its excipients.

          -  Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy
             within 1 week prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at
             baseline) from adverse events due to a previously administered agent.

          -  Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may
             qualify for the study.

          -  Note: If subject received major surgery, they must have recovered adequately from the
             toxicity and/or complications from the intervention prior to starting therapy.

          -  Has a known history of prior invasive malignancy except if the subject has undergone
             curative-intent therapy with no evidence of disease recurrence for 2 years prior to
             study entry. Exceptions include basal cell carcinoma of the skin, squamous cell
             carcinoma of the skin, superficial bladder cancer, low-risk prostate cancer or in situ
             cervical cancer.

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Subjects with previously treated brain metastases may participate provided
             they are stable (without evidence of progression by imaging for at least four weeks
             prior to the first dose of trial treatment and any neurologic symptoms have returned
             to baseline), have no evidence of new or enlarging brain metastases, and are not using
             steroids for at least 7 days prior to trial treatment. This exception does not include
             carcinomatous meningitis which is excluded regardless of clinical stability.

          -  Has active autoimmune disease that has required systemic treatment in the past 2.

          -  Has known history of, or any evidence of active, non-infectious pneumonitis.

          -  Has an active infection requiring systemic therapy.

          -  Has a history or current evidence of any condition, therapy, or laboratory abnormality
             that might confound the results of the trial, interfere with the subject's
             participation for the full duration of the trial, or is not in the best interest of
             the subject to participate, in the opinion of the treating investigator.

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.

          -  Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the pre-screening or screening visit
             through 120 days after the last dose of trial treatment.

          -  Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.

          -  Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

          -  Has received a live vaccine within 30 days of planned start of study therapy..
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer J. Knox, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer J. Knox, M.D.</last_name>
    <phone>416-946-2399</phone>
    <email>jennifer.knox@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer J. Knox, M.D.</last_name>
      <phone>416-946-2399</phone>
    </contact>
    <investigator>
      <last_name>Jennifer J. Knox, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>October 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>April 21, 2018</last_update_submitted>
  <last_update_submitted_qc>April 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

